心率与心律对心衰患者β受体阻滞剂获益的影响
该荟萃分析纳入11项双盲随机对照试验的个体患者数据,比较β受体阻滞剂与安慰剂。结果显示,窦性心律患者基线心率较高与全因死亡率增加相关(每10次/分校正HR 1.11),β受体阻滞剂降低死亡率(HR 0.73 vs 安慰剂),与基线心率无关;房颤患者心率与死亡率无关,β受体阻滞剂无死亡率获益(HR 0.96)。
要点
- 窦性心律心衰患者中,基线心率每增加10次/分,全因死亡风险校正HR 1.11。
- 窦性心律患者中β受体阻滞剂降低死亡率(HR 0.73 vs 安慰剂),与基线心率无关。
- 房颤患者中β受体阻滞剂对死亡率无影响(HR 0.96),与基线心率无关。
核心结论
- 无论治疗前心率如何,β受体阻滞剂均可降低窦性心律的射血分数降低心衰患者死亡率。
- 仅在窦性心律患者中,达到较低静息心率与更好预后相关(每增加10次/分HR 1.16)。
研究设计与样本
- Beta-Blockers in Heart Failure Collaborative Group对11项双盲随机对照试验的协调个体患者数据进行荟萃分析。
- 主要结局为全因死亡率,采用Cox比例风险模型分析基线和随机化后约6个月时测量的心率。
主要发现
- 窦性心律患者(n=14,166)基线心率较高与全因死亡率增加相关,每10次/分校正HR 1.11(95%CI 1.07-1.15,p<0.0001)。
- 房颤患者(n=3,034)基线心率与全因死亡率无关,每10次/分HR 1.03(95%CI 0.97-1.08,p=0.38)。
- β受体阻滞剂在窦性心律和房颤中均降低心室率12次/分。
- 窦性心律患者随机接受β受体阻滞剂者死亡率低于安慰剂组(HR 0.73,95%CI 0.67-0.79,p<0.001),与基线心率无关(交互p=0.35)。
- 房颤患者中β受体阻滞剂对死亡率无影响(HR 0.96,95%CI 0.81-1.12,p=0.58),与心率无关(交互p=0.48)。
临床怎么用
- 对于窦性心律的射血分数降低心衰患者,β受体阻滞剂可降低死亡率,不受基线心率影响。
- 对于房颤的射血分数降低心衰患者,β受体阻滞剂未显示死亡率获益。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The relationship between mortality and heart rate remains unclear for patients with heart failure with reduced ejection fraction in either sinus rhythm or atrial fibrillation (AF). OBJECTIVES: This analysis explored the prognostic importance of heart rate in patients with heart failure with reduced ejection fraction in randomized controlled trials comparing beta-blockers and placebo. METHODS: The Beta-Blockers in Heart Failure Collaborative Group performed a meta-analysis of harmonized individual patient data from 11 double-blind randomized controlled trials. The primary outcome was all-cause mortality, analyzed with Cox proportional hazard ratios (HR) modeling heart rate measured at baseline and approximately 6 months post-randomization. RESULTS: A higher heart rate at baseline was associated with greater all-cause mortality for patients in sinus rhythm (n = 14,166; adjusted HR: 1.11 per 10 beats/min; 95% confidence interval [CI]: 1.07 to 1.15; p < 0.0001) but not in AF (n = 3,034; HR: 1.03 per 10 beats/min; 95% CI: 0.97 to 1.08; p = 0.38). Beta-blockers reduced ventricular rate by 12 beats/min in both sinus rhythm and AF. Mortality was lower for patients in sinus rhythm randomized to beta-blockers (HR: 0.73 vs. placebo; 95% CI: 0.67 to 0.79; p < 0.001), regardless of baseline heart rate (interaction p = 0.35). Beta-blockers had no effect on mortality in patients with AF (HR: 0.96, 95% CI: 0.81 to 1.12; p = 0.58) at any heart rate (interaction p = 0.48). A lower achieved resting heart rate, irrespective of treatment, was associated with better prognosis only for patients in sinus rhythm (HR: 1.16 per 10 beats/min increase, 95% CI: 1.11 to 1.22; p < 0.0001). CONCLUSIONS: Regardless of pre-treatment heart rate, beta-blockers reduce mortality in patients with heart failure with reduced ejection fraction in sinus rhythm. Achieving a lower heart rate is associated with better prognosis, but only for those in sinus rhythm.
引用
- Kotecha D, Flather MD, Altman DG, et al. Heart Rate and Rhythm and the Benefit of Beta-Blockers in Patients With Heart Failure. J Am Coll Cardiol. 2017. PMID: 28467883. doi:10.1016/j.jacc.2017.04.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。